La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SIGNA Sports United a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SIGNA Sports United..

SIGNA Sports United (OTC:SSUTF) Azioni, Catena delle Opzioni

SIGNA Sports United NV is a group of specialist sports webshops powered by its sports commerce and technology platform. The company's segment includes Tennis; Bike and Outdoor and Teamsport. It generates maximum revenue from the Bike and Outdoor segment. Geographically, it derives a majority of revenue from Germany.

SIGNA Sports United NV Warrants (06/08/2025)

SIGNA Sports United NV

WIIM

TCMD

Tactile Systems Technology shares are trading lower after the company reported worse-than-expected Q1 sales results and lowered its FY25 sales guidance below estimates.

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.08 by 100 percent. This is a 500 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $621.00 million which missed the analyst consensus estimate of $633.58 million by 1.99 percent. This is a 1.80 percent increase over sales of $610.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

GBTG

Global Business Travel Q1 EPS $0.16 Beats $0.08 Estimate, Sales $621.00M Miss $633.58M Estimate

JP Morgan analyst Arun Jayaram maintains Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) with a Neutral and lowers the price target from $54 to $52.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Cactus, Lowers Price Target to $52

Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.01) by 13.86 percent. This is a 10.13 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $72.00 thousand which beat the analyst consensus estimate of $70.13 thousand by 2.67 percent. This is the same as the same period last year.

VRDN

Viridian Therapeutics Q1 EPS $(0.87) Beats $(1.01) Estimate, Sales $72.00K Beat $70.13K Estimate

Fabrinet Ordinary shares are trading lower. The company reported Q3 financial results

JP Morgan analyst Sebastiano Petti maintains Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) with a Neutral and lowers the price target from $325 to $222.

CABO

JP Morgan Maintains Neutral on Cable One, Lowers Price Target to $222

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading lower after the company reported Q1 financial results. Also, the company issued Q2 revenue guidance below estimates.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $30 price target.

Reiteration

BCRX

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) ("TransDigm" or the "Company") announced today that Kevin Stein will retire as President and Chief Executive Officer of TransDigm, following his more than ten years of service in senior leadership positions at the Company, effective as of September 30, 2025. Mike Lisman, the current Co-Chief Operating Officer of TransDigm, will succeed Mr. Stein as President and Chief Executive Officer. Mr. Stein will continue to serve as an advisor to the Company through March 31, 2026 to help facilitate the leadership transition. Additionally, he will continue to serve as a member of the Company's Board of Directors.

Management

TransDigm Group President And CEO Kevin Stein To Retire, Effective September 30, 2025; Mike Lisman To Succeed Stein as President and CEO

CORT

Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, HC Wainwright maintained a Buy rating on the stock but lowered its price target from $150 to $145.

JP Morgan analyst Rachel Vatnsdal maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Underweight and lowers the price target from $40 to $33.

TWST

JP Morgan Maintains Underweight on Twist Bioscience, Lowers Price Target to $33

Benchmark analyst David Williams reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $60 price target.

LSCC

Benchmark Reiterates Buy on Lattice Semiconductor, Maintains $60 Price Target

LMND

Lemonade shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

The Oracle of Omaha, Warren Buffett, during the 2025 Berkshire Hathaway Annual Meeting, expressed his disappointment over the depreciating U.S. dollar and said that no one would want to hold assets in a currency that was falling in value.
What Happened: Talking about the U.S. dollar, Buffett said, &#8220;You wouldn&#8217;t want to be owning anything that we thought was in a currency that was really going to hell. And that&#8217;s the biggest thing we are worried about United States currency.&#8221;
&#8220;I mean, the tendency of our government to want to debase its currency over time, there is no system that beats that,&#8221; he added, criticizing the government&#8217;s stance on a weaker dollar.
Buffett also underscored his concerns about the fiscal policy.
&#8220;You can pick dictators, you can pick representatives, you can do anything. But there will be a push toward a weaker currency. And of course, fiscal policy is what scares me in the United States because it&#8217;s made the way it is,&#8221; said Buffett.
See Also: <a href="https://www.benzinga.com/25/05/45213790/us-dollar-depreciation-is-cushioning-the-impact-of-tariffs-on-corporate-profits-says-expert-heres-how">US Dollar Depreciation Is Cushioning &#8216;The Impact Of Tariffs On Corporate Profits,&#8217; Says Expert</a>
Why It Matters: Analysts have criticized the U.S. government&#8217;s attempt to <a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-curren">weaken the U.S. dollar</a> in their analyses. Commentary from Chatham House expert David Lubin pointed out a "view of some within the Trump administration that the reserve currency status of the dollar is more of a burden to the U.S. economy than a blessing." 
According to him, the government&#8217;s &#8220;policy push" aims to weaken the dollar permanently against other currencies, hoping to reduce the trade deficit and attract manufacturers to the U.S.
However, Lubin strongly cautions against this approach, arguing that "if the international monetary system cannot rely on the dollar&#8217;s full convertibility, or its availability in a crisis, it is entering unknown territory. Undermining the dollar&#8217;s global status would not only transmit huge amounts of additional uncertainty to the global economy, but would be a needless act of self-harm for the U.S."
Price Action: As of the publication of this article, the U.S. Dollar Index Spot was 0.11% lower at the 99.7200 level. It has fallen by 8.02% on a year-to-date basis.
Whereas, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Monday. The SPY was down 0.57% to $563.51, while the QQQ declined 0.59% to $485.93, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
In premarket on Tuesday, SPY declined 0.61% and QQQ was down 0.84%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45214653/uber-could-win-the-robo-taxi-war-says-expert-analyst-predicts-75-gains-on-ride-hailing-cost-drop">Uber Could Win The &#8216;Robo Taxi War,&#8217; Says Expert: Analyst Predicts 75% Gains On Ride Hailing Cost Drop</a></li>
</ul>
Photo courtesy: mark reinstein / Shutterstock.com

Equities

Macro Economic Events

Market Summary

Broad U.S. Equity ETFs

Futures

Forex

Economics

Markets

ETFs

General

Warren Buffett Expresses Disappointment Over Dollar Depreciation: Don't Want To Own Assets In A Currency That Is 'Really Going To Hell'

<ul>
<li>Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor growth in mice models.</li>
<li>The cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.</li>
<li>A Phase 1b Study of the addition of Aramchol to Regorafenib in patients with advanced GI cancers is planned to be initiated at VCU's Massey Cancer Center in Q4 2025.</li>
<li>Leveraging on its long-standing experience in liver and metabolic diseases, Galmed plans to advance the novel combination oncology program in parallel to the recently announced Semaglutide GLP-1 development.</li>
</ul>
TEL AVIV, Israel, May 6, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.

GLMD

Galmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models

Clorox shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY25 sales guidance below estimates.

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $158 to $160.

NBIX

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160

Benchmark analyst David Williams maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $60 to $50.

Benchmark Maintains Buy on ON Semiconductor, Lowers Price Target to $50

AngloGold Ashanti shares are trading higher. The company paused its discussions about its joint venture with Gold Fields to focus on improving their standalone performance at their respective sites.

Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGE#NYSE">MSGE</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.23 by 26.09 percent. This is a 183.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $242.47 million which beat the analyst consensus estimate of $231.13 million by 4.90 percent. This is a 6.20 percent increase over sales of $228.31 million the same period last year.

Comments

SIGNA Sports United

SIGNA Sports United (SSUTF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO